Quality-of-Life Assessment Following Single-Fraction Stereotactic Radiotherapy for Inoperable Primary and Oligometastatic Lung Tumors

What this Trial Is About

Pulmonary tumors, whether primary or metastatic, pose significant challenges in cancer care, with lung cancer being a leading cause of death in France. This study evaluates the impact of single-fraction stereotactic body radiotherapy SBRT on quality of life in patients with inoperable or surgery-refusing primary non-small cell lung cancer NSCLC or oligometastatic lung tumors. It aims to provide insights on how this treatment affects patients well-being using a detailed, disease-specific quality of life questionnaire. Patients receive a single high-dose radiation session of 34 Gy targeted precisely at lung tumors. This SBRT approach is delivered in one session, which has been adopted during the COVID-19 pandemic to reduce patient visits while maintaining treatment effectiveness. The study includes both newly treated patients followed prospectively and patients treated previously whose data will be analyzed retrospectively. The treatments are carried out at two cancer centers in France. Participants complete standardized quality of life questionnaires before treatment and then at 1, 3, 6, 9, and 12 months after treatment. Researchers will assess overall quality of life, lung cancer-specific symptoms, treatment tolerance, and efficacy through clinical records and questionnaires. The study also reviews dosimetric details of the radiation delivery. This follow-up allows a comprehensive understanding of treatment effects on patients daily functioning and symptoms over one year.

Single-Fraction Pulmonary Ablative Radiotherapy Outcomes and Quality-of-life Workup